Sotac Pharmaceuticals Ltd Stock Price Today (NSE: SOTAC)
Fundamental Score
Sotac Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Sotac Pharmaceuticals Ltd share price today is ₹110.00, up +0.00% on NSE/BSE as of 18 March 2026. Sotac Pharmaceuticals Ltd (SOTAC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹153.04 (Cr). The 52-week high for SOTAC share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 17.88x, SOTAC is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.71% and a debt-to-equity ratio of 0.69.
Sotac Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sotac Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sotac Pharmaceuticals Share Price: A ROCE-Focused Analysis
The pharmaceutical industry, often considered recession-resistant, still demands rigorous financial scrutiny. Generics, in particular, face pricing pressures, necessitating a keen focus on efficient capital deployment. This analysis focuses on Sotac Pharmaceuticals share price, currently trading at ₹118.300003, and examines its Return on Capital Employed (ROCE) relative to its valuation and peer performance.
Sotac Pharmaceuticals Ltd boasts a PE ratio of 17.88 and an ROCE of 15.06%. The ROCE metric is crucial because it indicates how effectively the company uses its capital to generate profits. A 15.06% ROCE suggests reasonable efficiency, but its true significance lies in comparison with sector peers and historical performance. A higher ROCE generally implies a stronger competitive advantage, or "moat," as the company can generate more profit from its investments than its competitors. This allows for greater reinvestment opportunities and shareholder value creation.
To understand Sotac's competitive position, it is imperative to compare its ROCE with companies like
Mankind Pharma Ltd and others in the pharmaceutical sector. Furthermore, factors beyond pure financial metrics, such as management quality, play a significant role. While ROCE provides a quantitative measure of efficiency, the execution capabilities of the management team significantly impact future performance. For example, Mankind Pharma Ltd. may command a premium valuation due to perceived superior management expertise in navigating the complex regulatory landscape and successfully launching new products, despite potentially having a similar ROCE.Ultimately, the sustainability of Sotac Pharmaceuticals' 15.06% ROCE and its impact on long-term shareholder value depends on factors such as its ability to maintain pricing power, control costs, and innovate. It's important to monitor Sotac's strategic initiatives and market dynamics to assess the future trajectory of its ROCE and consequently, its valuation. This analysis forms a small part of a comprehensive, 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a holistic view of Sotac Pharmaceuticals Ltd.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sotac Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SOTAC across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (15.71%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.06%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 17.88 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (28.27%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (27.65% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (82.29% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (149.51% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Revenue Contraction (-29.63%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Sotac Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Sotac Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About SOTAC (Sotac Pharmaceuticals Ltd)
Sotac Pharmaceuticals Ltd (SOTAC) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹153.04 (Cr). Sotac Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 15.71% and a ROCE of 15.06%. The debt-to-equity ratio stands at 0.69, reflecting the company's capital structure. Investors tracking SOTAC share price can monitor key metrics including P/E ratio, promoter holding of 72.85%, and quarterly earnings growth.
Company Details
SOTAC Share Price: Frequently Asked Questions
What is the current share price of Sotac Pharmaceuticals Ltd (SOTAC)?
As of 18 Mar 2026, 10:26 am IST, Sotac Pharmaceuticals Ltd share price is ₹110.00. The SOTAC stock has a market capitalisation of ₹153.04 (Cr) on NSE/BSE.
Is SOTAC share price Overvalued or Undervalued?
SOTAC share price is currently trading at a P/E ratio of 17.88x, compared to the industry average of 31.77x. Based on this relative valuation, the Sotac Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of SOTAC share price?
The 52-week high of SOTAC share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Sotac Pharmaceuticals Ltd share price?
Key factors influencing SOTAC share price include quarterly earnings growth (Sales Growth: -29.63%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sotac Pharmaceuticals Ltd a good stock for long-term investment?
Sotac Pharmaceuticals Ltd shows a 5-year Profit Growth of 149.51% and an ROE of 15.71%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.69 before investing in SOTAC shares.
How does Sotac Pharmaceuticals Ltd compare with its industry peers?
Sotac Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare SOTAC share price P/E of 17.88x and ROE of 15.71% against the industry averages to determine competitive standing.
What is the P/E ratio of SOTAC and what does it mean?
SOTAC share price has a P/E ratio of 17.88x compared to the industry average of 31.77x. Investors pay ₹18 for every ₹1 of annual earnings.
How is SOTAC performing according to Bull Run's analysis?
SOTAC has a Bull Run fundamental score of 57.5/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SOTAC belong to?
SOTAC operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sotac Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for SOTAC?
SOTAC has an ROE of 15.71%, which indicates excellent management efficiency. ROE measures how efficiently Sotac Pharmaceuticals Ltd generates profits from shareholders capital.
How is SOTAC debt-to-equity ratio and what does it indicate?
SOTAC has a debt-to-equity ratio of 0.69, which indicates moderate leverage that should be monitored.
What is SOTAC dividend yield and is it a good dividend stock?
SOTAC offers a dividend yield of 0.07%, meaning you receive ₹0.07 annual dividend for every ₹100 invested in Sotac Pharmaceuticals Ltd shares.
How has SOTAC share price grown over the past 5 years?
SOTAC has achieved 5-year growth rates of: Sales Growth 27.65%, Profit Growth 149.51%, and EPS Growth 82.29%.
What is the promoter holding in SOTAC and why does it matter?
Promoters hold 72.85% of SOTAC shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sotac Pharmaceuticals Ltd.
What is SOTAC market capitalisation category?
SOTAC has a market capitalisation of ₹153 crores, placing it in the Small-cap category.
How volatile is SOTAC stock?
SOTAC has a beta of N/A. A beta > 1 suggests the Sotac Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SOTAC operating profit margin trend?
SOTAC has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is SOTAC quarterly performance?
Recent quarterly performance shows Sotac Pharmaceuticals Ltd YoY Sales Growth of -29.63% and YoY Profit Growth of 28.27%.
What is the institutional holding pattern in SOTAC?
SOTAC has FII holding of 16.14% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Sotac Pharmaceuticals Ltd stock.